Synergistic chemoimmunotherapy using pirarubicin-loaded tumor-derived extracellular vesicles for triple-negative breast cancer (TNBC)
European Journal of Pharmaceutical Sciences · 2025
DOI: 10.1016/j.ejps.2025.107331 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2025. Verfasst von Quanwu Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Breast Surgery Department of Gansu Provincial People's Hospital, Shenhan Yu School of Stomatology, Lanzhou University. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Extracellular Vesicles, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Gansu Province.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) has an extremely poor clinical prognosis due to the lack of effective therapeutic targets and high heterogeneity. In this study, we developed a synergistic chemoimmunotherapy based on tumor-derived extracellular vesicles (TEVs), which induces immunogenic cell death (ICD) and remodels the immunosuppressive tumor microenvironment (TME) by delivering pirarubicin (THP). 4T1 TNBC cell derived TEVs were loaded with THP via overnight co-incubation at room temperature (THP@TEVs), which exhibited excellent tumor targeting and biocompatibility. In vitro experiments demonstrated that THP@TEVs was efficiently internalized by tumor cells, and compared to the free THP group, THP@TEVs significantly increased the apoptosis rate (70.25 % vs. 25.61 %, p < 0.001, n = 3)". In vivo studies showed that THP@TEVs significantly activated the ICD effect and promoted CD8⁺ T-cell infiltration by enhancing calreticulin (CRT) membrane translocation and high mobility group protein B1 (HMGB1) release (CRT increased≈3 fold; HMGB1 increased≈3.1 fold). In addition, compared with the control group, the tumor volume in the THP@TEVs group was reduced by approximately 62.1 % (p < 0.001, n = 5) and no histopathological changes were observed in major organs (such as heart, liver, spleen, lungs, and kidneys) upon H&E staining. This study provides a precise, low-toxicity chemotherapy and immune synergistic strategy for TNBC and expands the potential of TEVs in tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast Surgery Department of Gansu Provincial People's Hospital, Shenhan Yu School of Stomatology, Lanzhou University.
- Breast Surgery Department of Gansu Provincial People's Hospital, Shenhan Yu School of Stomatology, Lanzhou University. Electronic address: 2750519850@qq.com.
Förderung
- Natural Science Foundation of Gansu Province
Zitieren
APA
Sun, Q., Yu, S., Shi, R., Xu, M., Ma, P., & Lv, F. Y. (2025). Synergistic chemoimmunotherapy using pirarubicin-loaded tumor-derived extracellular vesicles for triple-negative breast cancer (TNBC). European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2025.107331
Vancouver
Sun Q, Yu S, Shi R, Xu M, Ma P, Lv FY. Synergistic chemoimmunotherapy using pirarubicin-loaded tumor-derived extracellular vesicles for triple-negative breast cancer (TNBC). European Journal of Pharmaceutical Sciences. 2025. doi:10.1016/j.ejps.2025.107331
BibTeX
@article{Sun2025,
author = {Sun, Quanwu and Yu, Shenhan and Shi, Rong and Xu, Meng and Ma, Peilan and Lv, Feng Yan},
title = {Synergistic chemoimmunotherapy using pirarubicin-loaded tumor-derived extracellular vesicles for triple-negative breast cancer (TNBC)},
journal = {European Journal of Pharmaceutical Sciences},
year = {2025},
doi = {10.1016/j.ejps.2025.107331}
}
EUVIMED